Transcriptomics

Dataset Information

0

Targeting Senescent Hepatocytes for Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease and Multi-organ Dysfunction


ABSTRACT: Senescent hepatocytes accumulate in metabolic dysfunction-associated steatotic liver disease (MASLD) and are linked to worse clinical outcomes. However, their heterogeneity and lack of specific markers have made them difficult to target therapeutically. Here, we define a senescent hepatocyte gene signature (SHGS) using in vitro and in vivo models and show that it tracks with MASLD progression/regression across mouse models and large human cohorts. Single-nucleus RNA-sequencing and functional studies reveal that SHGS+ hepatocytes originate from p21+ cells, lose key liver functions and release factors that drive disease progression. One such factor, GDF15, increases in circulation alongside SHGS+ burden and disease progression. Through chemical screening, we identify senolytics that selectively eliminate SHGS+ hepatocytes and improve MASLD in mice. Notably, SHGS enrichment also correlates with dysfunction in other organs. These findings establish SHGS+ hepatocytes as key drivers of MASLD and highlight a potential therapeutic strategy for targeting senescent cells in liver disease and beyond.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE288534 | GEO | 2025/02/21

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2025-03-04 | GSE286394 | GEO
2025-03-05 | PXD051911 | Pride
2025-01-20 | GSE279512 | GEO
2024-06-17 | GSE246221 | GEO
| PRJNA1218242 | ENA
2024-03-01 | GSE238173 | GEO
2025-01-27 | GSE288077 | GEO
2024-03-01 | GSE238201 | GEO
2024-10-01 | GSE273523 | GEO
2024-09-12 | GSE254841 | GEO